Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Motonori Kimura

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Ryoikibetsu Shokogun Shirizu|July 25, 2003
[Meige's syndrome]Motonori Kimura, Nobutaka Motohashi
Plos One|July 28, 2025
Identification of risk factors and development of a predictive model in patients using cefmetazole for international normalized ratio elevationTakaya Namiki, Yuta Yokoyama, Motonori Kimura, et al.
Biological & Pharmaceutical Bulletin|May 7, 2025
Efficacy of De-Escalation to Cefmetazole in Patients with Bacteremic Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coliTakaya Namiki, Yuta Yokoyama, Motonori Kimura, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 18, 2022
Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serumEmi Ishikawa, Yuta Yokoyama, Haruna Chishima, et al.
Jac-Antimicrobial Resistance|May 21, 2026
Age and body weight-adjusted infusion rate (mg/kg/h) as risk factors for vancomycin infusion reaction in patients receiving perioperative antimicrobial prophylaxis: a retrospective cohort studyOsamu Iketani, Shunsuke Uno, Masayoshi Shinjoh, et al.
Investigational New Drugs|January 13, 2023
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational StudyEmi Ishikawa, Yuta Yokoyama, Haruna Chishima, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Ryoikibetsu Shokogun Shirizu|July 25, 2003
[Meige's syndrome]Motonori Kimura, Nobutaka Motohashi
Plos One|July 28, 2025
Identification of risk factors and development of a predictive model in patients using cefmetazole for international normalized ratio elevationTakaya Namiki, Yuta Yokoyama, Motonori Kimura, et al.
Biological & Pharmaceutical Bulletin|May 7, 2025
Efficacy of De-Escalation to Cefmetazole in Patients with Bacteremic Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coliTakaya Namiki, Yuta Yokoyama, Motonori Kimura, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 18, 2022
Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serumEmi Ishikawa, Yuta Yokoyama, Haruna Chishima, et al.
Jac-Antimicrobial Resistance|May 21, 2026
Age and body weight-adjusted infusion rate (mg/kg/h) as risk factors for vancomycin infusion reaction in patients receiving perioperative antimicrobial prophylaxis: a retrospective cohort studyOsamu Iketani, Shunsuke Uno, Masayoshi Shinjoh, et al.
Investigational New Drugs|January 13, 2023
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational StudyEmi Ishikawa, Yuta Yokoyama, Haruna Chishima, et al.
Pageof 1